Yanxuan Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanxuan Wen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyuan Li
Department of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, Changsha, China
2 shared publications - Haixia Zhang
School of Biomedical Engineering, Capital Medical University
1 shared publication - Jiaxing Li
Department of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, Changsha, 410013, China
1 shared publication - Nouman Amjad
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, China
1 shared publication Omar Mukama
CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510663, China
1 shared publicationRongqi Huang
CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510663, China
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by MDPI AG in Preprints.org
The Classic WNT Pathway Modulates Umbilical Cord-Derived Mesenchymal Stromal Cells in Restoring Hepatic Microenvironment Homeostasis Related Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) specifically includes the stage of simple fatty liver and the stage of hepatitis. Recent research found mesenchymal stem cell therapy for NAFLD. Mesenchymal stem cells regulate metabolic pathways and energy transport pathways in disease models, reducing the synthesis and utilisation of glucose and fatty acids and restoring the homeostasis of the internal microenvironment. For areas with more severe damage, umbilical cord mesenchymal stem cells (UCMSC) are used for regenerative repair with classic Wnt pathway. The text explores the therapeutic effects of UCMSCs on hepatitis and the surrounding environment from a multifunctional perspective. Mesenchymal stem cells release exosomes in a paracrine manner into the damaged areas of the liver, promoting the differentiation and development of hepatic progenitor cells into hepatocytes, reducing differentiation into cholangiocytes, while assisting hepatic progenitor cells in resisting the progression of inflammation and fibrosis, and promoting the normal function of adaptive immune responses.
- 23 July 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Classic WNT Pathway Modulates Umbilical Cord-Derived Mesenchymal Stromal Cells in Restoring Hepatic Microenvironment Homeostasis Related Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) specifically includes the stage of simple fatty liver and the stage of hepatitis. Recent research found mesenchymal stem cell therapy for NAFLD. Mesenchymal stem cells regulate metabolic pathways and energy transport pathways in disease models, reducing the synthesis and utilisation of glucose and fatty acids and restoring the homeostasis of the internal microenvironment. For areas with more severe damage, umbilical cord mesenchymal stem cells (UCMSC) are used for regenerative repair with classic Wnt pathway. The text explores the therapeutic effects of UCMSCs on hepatitis and the surrounding environment from a multifunctional perspective. Mesenchymal stem cells release exosomes in a paracrine manner into the damaged areas of the liver, promoting the differentiation and development of hepatic progenitor cells into hepatocytes, reducing differentiation into cholangiocytes, while assisting hepatic progenitor cells in resisting the progression of inflammation and fibrosis, and promoting the normal function of adaptive immune responses.
- 31 March 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (6) , 1107-1118
New insights on mesenchymal stem cells therapy from the perspective of the pathogenesis of nonalcoholic fatty liver disease
- 31 March 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (6) , 1107-1118
New insights on mesenchymal stem cells therapy from the perspective of the pathogenesis of nonalcoholic fatty liver disease